4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

MENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the appointment of Chris Martin to its Board of Directors. Additionally, Cameron Turtle, DPhil, resigned from the Board effective December 11, 2025. "As we rapidly advance our co-lead programs through development, I'm pleased to announce this board transition at Oruka," said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. "Chris's expertise can bring tremendous value to the compan

8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)

10-Q - Oruka Therapeutics, Inc. (0000907654) (Filer)

8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)

424B5 - Oruka Therapeutics, Inc. (0000907654) (Filer)

424B5 - Oruka Therapeutics, Inc. (0000907654) (Filer)

424B5 - Oruka Therapeutics, Inc. (0000907654) (Filer)

8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)

424B7 - Oruka Therapeutics, Inc. (0000907654) (Filer)

DEFA14A - Oruka Therapeutics, Inc. (0000907654) (Filer)

DEF 14A - Oruka Therapeutics, Inc. (0000907654) (Filer)

Piper Sandler initiated coverage of Oruka Therapeutics with a rating of Overweight and set a new price target of $75.00

Jefferies initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $45.00

Guggenheim initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $60.00

Barclays initiated coverage of Oruka Therapeutics with a rating of Overweight and set a new price target of $48.00

BTIG Research initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $44.00

Wolfe Research initiated coverage of Oruka Therapeutics with a rating of Outperform and set a new price target of $20.00

Stifel initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $49.00

H.C. Wainwright initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $45.00

Leerink Partners initiated coverage of Oruka Therapeutics with a rating of Outperform and set a new price target of $44.00

TD Cowen initiated coverage of Oruka Therapeutics with a rating of Buy

DENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts. Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store That is why so much attention is focused on companies that are approaching pivotal readouts or are fresh off meaningful Phase 2 updates that could materially

MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its presentation at the 2026 Jefferies Global Healthcare Conference, taking place in New York, NY from June 2-4, 2026. Presentation DetailsDate: Wednesday, June 3rd, 2026Presentation Time: 3:45PM ET A webcast and replay of Oruka's presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations. About Oruka TherapeuticsOruka Therapeutics is de

ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027 Post-offering cash, cash equivalents and marketable securities expected to fund Company through BLA for ORKA-001 MENLO PARK, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today reported first quarter 2026 financial results and provided a corporate upda

SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced three senior leadership appointments. Christopher Martin has joined the Company's Board of Directors. Mark Zappia has joined as Senior Vice President, Commercial, where he will spearhead the Company's commercial function. Jim Willis has joined as Vice President of Sales and Sales Enablement, where he will lead the field force. Mr. Martin most recently served as Chief Commercia

Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional targetSAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") and Oruka Therapeutics, Inc. (NASDAQ:ORKA) ("Oruka") today announced that Halozyme's wholly‑owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Oruka.Under the agreement, Oruka has licensed Halozyme's Hypercon™ technology for use with ORKA‑001, in development for psoriasis and related inflammatory diseases, and up to one additional target. Hypercon™ is an innovative microparticle technology that allows for

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (NASDAQ:ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced the pricing of its upsized underwritten public offering of 9,660,000 shares of its common stock at a price to the public of $72.50 per share. The gross proceeds to Oruka from this offering are expected to be approximately $700.4 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. In additio

MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (NASDAQ:ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Oruka expects to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of its common stock at the public offering price, less underwriting discounts and co

ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term EVERLAST-A data expected in 2H 2026 Management to host a conference call today at 8:00 a.m. ET MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal ant

MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis on Monday, April 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Oruka Therapeutics' live webcast of the EVERLAST-A results will begin on Monday, April 27th, at 8:00 a.m. ET. The live webcast can be accessed via

ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027 $479.6 million in cash, cash equivalents and marketable securities MENLO PARK, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today reported fourth quarter and full year 2025 financial results and provided a corporate update. "We are very pleased with

SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

SC 13G - Oruka Therapeutics, Inc. (0000907654) (Subject)

ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term EVERLAST-A data expected in 2H 2026 Management to host a conference call today at 8:00 a.m. ET MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal ant

MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis on Monday, April 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Oruka Therapeutics' live webcast of the EVERLAST-A results will begin on Monday, April 27th, at 8:00 a.m. ET. The live webcast can be accessed via